Standard-of-care anticancer treatment (retrospective): Treatments received as part of routine clinical care and recorded retrospectively in medical records, which may include surgery, radiotherapy, systemic chemotherapy, targeted therapy, and/or immunotherapy. No study-related intervention will be assigned or provided. This observational study only collects and analyzes de-identified real-world treatment and outcome data.
Study summary
This study is a multi-center, retrospective observational study of patients with lung NUT carcinoma. Existing clinical records from participating hospitals will be reviewed to describe patient characteristics, treatments, and outcomes. No study-related interventions will be performed. Data will be de-identified to protect patient privacy.
Eligibility
Sex
ALL
Min age
—
Max age
—
Healthy volunteers
No
Inclusion Criteria:
* Pathologically confirmed pulmonary (lung) NUT carcinoma.
* Evidence of NUT immunohistochemistry (IHC) positivity and/or NUTM1 rearrangement/fusion, per local pathology report.
* Diagnosed and/or treated at a participating hospital during the study period.
* Availability of sufficient medical record data to abstract key baseline characteristics, treatments, and outcomes.
Exclusion Criteria:
* Primary tumor site not in the lung.
* Records insufficient to confirm the diagnosis of pulmonary NUT carcinoma.
* No follow-up or outcome information available after diagnosis (insufficient for survival/outcome assessment).
Primary outcome measure(s)
Progression-Free Survival (PFS) — From diagnosis through study completion (up to May 2026) Time from initial diagnosis (index date) to first documented disease progression per routine clinical assessment or death from any cause, whichever occurs first.
Trial sites (1)
Facility
City
Region
Status
Chongqing University Three Gorges Hospital
Chongqing
Chongqing Municipality
More Three Gorges Hospital of Chongqing University trials in China
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time.